| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | selumetinib:vorinostat (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |